Biotech

Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News

Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its stock price…

Read More »

Therma Bright Announces Venowave Nationwide US Distribution Partner

Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a developer and investment partner in a wide range of leading-edge, proprietary…

Read More »

US Port Strike Threatens Supply of Popular Weight-Loss Drugs Ozempic, Wegovy, Mounjaro, and Zepbound

The ongoing US port strike on the East and Gulf coasts is causing significant disruptions to pharmaceutical supply chains, particularly…

Read More »

Therma Bright to Conduct Non-Brokered LIFE Financing and Private Placement for Up to $6 Million

Proprietary diagnostic and medical device technologies developer and investment partner Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) announced that…

Read More »

Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with…

Read More »

Therma Bright’s Investment Company InStatin Signs Discovery Study Agreement With Mountain West Research

Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a developer and investment partner in cutting-edge diagnostic and medical device technologies,…

Read More »

$20M Healthcare Stock Breaks Out After Rising 1,700% on Medicare and Medicaid Clearance, Here’s What’s Being Announced in the Coming Months in a 25X Larger Market

Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a burgeoning name in the medical device industry, has achieved a significant…

Read More »

Therma Bright Adds Experienced Pharma and Medical Device Industry Veteran to Advisory Board

Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a developer and investment partner in advanced diagnostic and medical device technologies,…

Read More »

Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News

Tempest Therapeutics (NASDAQ: TPST), a clinical-stage biotechnology firm focused on innovative cancer therapies, announced a significant milestone on Thursday as…

Read More »

Sangamo Therapeutics Inks $1.95B Deal With Genentech to Target Alzheimer’s, SGMO Stock Pops 29%

In a significant advancement for the field of genomic medicine, Sangamo Therapeutics has entered a landmark license agreement with Genentech,…

Read More »
Back to top button